BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 28178345)

  • 21. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
    Gaudio E; Tarantelli C; Kwee I; Barassi C; Bernasconi E; Rinaldi A; Ponzoni M; Cascione L; Targa A; Stathis A; Goodstal S; Zucca E; Bertoni F
    Ann Oncol; 2016 Jun; 27(6):1123-1128. PubMed ID: 26961147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
    Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
    Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
    Meadows SA; Vega F; Kashishian A; Johnson D; Diehl V; Miller LL; Younes A; Lannutti BJ
    Blood; 2012 Feb; 119(8):1897-900. PubMed ID: 22210877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
    Kim JH; Kim WS; Ryu K; Kim SJ; Park C
    Leuk Lymphoma; 2016; 57(6):1413-22. PubMed ID: 26699656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
    Hofland T; de Weerdt I; Ter Burg H; de Boer R; Tannheimer S; Tonino SH; Kater AP; Eldering E
    J Immunol; 2019 Oct; 203(8):2100-2109. PubMed ID: 31511358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
    Murali I; Kasar S; Naeem A; Tyekucheva S; Khalsa JK; Thrash EM; Itchaki G; Livitz D; Leshchiner I; Dong S; Fernandes SM; Getz G; Johnson A; Brown JR
    Blood; 2021 Jul; 138(1):44-56. PubMed ID: 33684943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of B-cell receptor signalling in B-cell malignancies.
    Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
    J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
    Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.